Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of Palbociclib in
combination with investigational (experimental) drug, CPX-351 and evaluate the efficacy of
Palbociclib in combination with chemotherapy as measured by overall response rate (ORR), i.e.
complete response (CR) and CR with incomplete blood count recovery (CRi) by 2003 IWG
criteria.